<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="1479">
  <stage>Registered</stage>
  <submitdate>20/02/2007</submitdate>
  <approvaldate>20/02/2007</approvaldate>
  <nctid>NCT00438958</nctid>
  <trial_identification>
    <studytitle>Sibling Donor Peripheral Stem Cell Transplant or Sibling Donor Bone Marrow Transplant in Treating Patients With Hematologic Cancers or Other Diseases</studytitle>
    <scientifictitle>A Randomized Multicentre Study Comparing G-CSF Mobilized Peripheral Blood and G-CSF Stimulated Bone Marrow in Patients Undergoing Matched Sibling Transplantation for Hematologic Malignancies</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>CBMTG-0601</secondaryid>
    <secondaryid>CDR0000528289</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Chronic Myeloproliferative Disorders</healthcondition>
    <healthcondition>Graft Versus Host Disease</healthcondition>
    <healthcondition>Leukemia</healthcondition>
    <healthcondition>Lymphoma</healthcondition>
    <healthcondition>Myelodysplastic Syndromes</healthcondition>
    <healthcondition>Secondary Myelofibrosis</healthcondition>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Lymphoma (non Hodgkin's lymphoma) - High grade lymphoma</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Lymphoma (non Hodgkin's lymphoma) - Low grade lymphoma</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Other</conditioncode1>
      <conditioncode2>Research that is not of generic health relevance and not applicable to specific health categories listed above</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Leukaemia - Acute leukaemia</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Leukaemia - Chronic leukaemia</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Children's - Leukaemia &amp; Lymphoma</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Blood </conditioncode1>
      <conditioncode2>Haematological diseases</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Blood </conditioncode1>
      <conditioncode2>Other blood disorders</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Inflammatory and Immune System</conditioncode1>
      <conditioncode2>Other inflammatory or immune system disorders</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Musculoskeletal</conditioncode1>
      <conditioncode2>Other muscular and skeletal disorders</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Human Genetics and Inherited Disorders</conditioncode1>
      <conditioncode2>Other human genetics and inherited disorders</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Other interventions - filgrastim
Treatment: surgery - allogeneic bone marrow transplantation
Treatment: surgery - peripheral blood stem cell transplantation

Active Comparator: Arm I - Patients undergo filgrastim (G-CSF)-mobilized sibling donor peripheral blood SCT on day 0.

Experimental: Arm II - Patients undergo G-CSF-mobilized sibling donor bone marrow transplantation on day 0.


Other interventions: filgrastim
Given on day 0.

Treatment: surgery: allogeneic bone marrow transplantation
Given on day 0

Treatment: surgery: peripheral blood stem cell transplantation
Given on day 0

</interventions>
    <comparator />
    <control />
    <interventioncode>Other interventions interventions</interventioncode>
    <interventioncode>Treatment: surgery</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Time to treatment failure (extensive chronic graft-versus-host disease [GVHD], relapse, death)</outcome>
      <timepoint />
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Time to neutrophil recovery</outcome>
      <timepoint />
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Primary graft failure</outcome>
      <timepoint />
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Overall survival</outcome>
      <timepoint />
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Quality of life</outcome>
      <timepoint />
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Time to acute GVHD</outcome>
      <timepoint />
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Time to chronic GVHD</outcome>
      <timepoint />
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Chronic GVHD details</outcome>
      <timepoint />
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Cost</outcome>
      <timepoint />
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Detailed donor and patient self-reported outcomes</outcome>
      <timepoint />
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>DISEASE CHARACTERISTICS:

          -  Diagnosis of one of the following hematologic malignancies:

               -  Acute myeloid leukemia in first complete remission or second complete remission

               -  Chronic myeloid leukemia in chronic or accelerated phase

               -  Myelodysplasia, including any of the following:

                    -  Refractory anemia (RA)

                    -  RA with ringed sideroblasts

                    -  RA with excess blasts (RAEB) I

                    -  RAEB in transformation

                    -  Chronic myelomonocytic leukemia

               -  Other hematologic malignancy for which sibling donor stem cell transplantation
                  with a myeloablative conditioning regimen is appropriate, including any of the
                  following:

                    -  Indolent non-Hodgkin's lymphoma (NHL)

                    -  Aggressive NHL

                    -  Chronic lymphocytic leukemia

                    -  Hodgkin's lymphoma

                    -  Myelofibrosis

                    -  Hematologic malignancy not otherwise specified

          -  HLA-matched sibling donor available meeting all of the following criteria:

               -  6/6 HLA match

                    -  HLA typing performed by serologic or DNA methodology for A and B and by DNA
                       methodology for DRB1 (intermediate resolution)

               -  Not identical twin with patient

        PATIENT CHARACTERISTICS:

          -  ECOG performance status 0-2

          -  Not pregnant or nursing

          -  Negative pregnancy test

          -  Fertile patients must use effective contraception

          -  No cognitive, linguistic, or emotional difficulty that would preclude participation in
             the quality-of-life component of the study

          -  Able to communicate in English or French

          -  No HIV antibody positivity

        PRIOR CONCURRENT THERAPY:

          -  Not specified</inclusivecriteria>
    <inclusiveminage>16</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>65</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria />
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment />
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3</phase>
    <anticipatedstartdate />
    <actualstartdate>1/03/2007</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize>230</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>SA,VIC</recruitmentstate>
    <hospital>Institute of Medical and Veterinary Science - Adelaide</hospital>
    <hospital>Royal Melbourne Hospital - Parkville</hospital>
    <postcode>5000 - Adelaide</postcode>
    <postcode>3050 - Parkville</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Washington</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>British Columbia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Manitoba</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Nova Scotia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Ontario</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Quebec</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Auckland</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Saudi Arabia</country>
      <state>Riyadh</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Other</primarysponsortype>
    <primarysponsorname>The Canadian Blood and Marrow Transplant Group</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
    <othercollaborator>
      <othercollaboratortype>Government body</othercollaboratortype>
      <othercollaboratorname>National Cancer Institute (NCI)</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>RATIONALE: Giving chemotherapy before a donor peripheral stem cell transplant or bone marrow
      transplant using stem cells from a brother or sister that closely match the patient's stem
      cells, helps stop the growth of cancer or abnormal cells. It also helps stop the patient's
      immune system from rejecting the donor's stem cells. The donated stem cells may replace the
      patient's immune cells and help destroy any remaining cancer or abnormal cells
      (graft-versus-tumor effect). Sometimes the transplanted cells from a donor can also make an
      immune response against the body's normal cells. Giving colony-stimulating factors, such as
      G-CSF, to the donor helps the stem cells move from the bone marrow to the blood so they can
      be collected and stored. Giving methotrexate and cyclosporine before and after transplant may
      stop this from happening. It is not yet known whether a donor peripheral stem cell transplant
      is more effective than a donor bone marrow transplant in treating hematologic cancers or
      other diseases.

      PURPOSE: This randomized phase III trial is studying filgrastim-mobilized sibling donor
      peripheral stem cell transplant to see how well it works compared with sibling donor bone
      marrow transplant in treating patients with hematologic cancers or other diseases.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT00438958</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Stephen Couban, MD</name>
      <address>Cancer Care Nova Scotia</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>